← SynDRA
ALOGLIPTIN
SynDRA canonical compound SYN0006976 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | DPP4 |
|---|
| Mechanism of action | Dipeptidyl peptidase inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
Mechanisms of action (all sources)
- Dipeptidyl peptidase inhibitor
- DPP4 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP3A4
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
- OPRK1
- OPRM1
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2B
- ABL1
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HDAC6
- GSK3B
- GIPR
- GHSR
- GCGR
- HTR7
- MAPK1
- FGFR2
- PGR
- TBXA2R
- TACR1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC29A1
- PTGS2
- PREP
- PDE4D
- MC3R
- PDE3A
- OPRD1
- NTSR1
Drug classes
- Dipeptidyl-Peptidase IV Inhibitors
- Enzyme Inhibitors
- Hormones
- Hypoglycemic Agents
- Incretins
- Protease Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitor
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- KAZANO
- NESINA
- Nesina
- OSENI
- vipidia
- alogliptin benzoate
- nesina
- Alogliptine
- Alogliptina
- Vipidia
- UNII-JHC049LO86
- alogliptina
- SYR-322
- JHC049LO86
- CHEBI:72323
- AK322010
- Alogliptin [INN]
- Alogliptin (SYR-322)
- alogliptinum
- alogliptine
- HSDB 8203
- SYR322
- ALOGLIPTIN [MI]
- ALOGLIPTIN [VANDF]
- ALOGLIPTIN [WHO-DD]
- SCHEMBL121028
- CHEMBL376359
- GTPL6319
- BDBM16285
- HY-A0023A
- DTXSID90234130
- AMY22119
- EX-A5446
- Alogliptin pound SYR-322 pound(c)
- MFCD09833196
- s2868
- s5365
- ZINC14961096
Reported adverse events
- Hypersensitivity
- Stevens-Johnson syndrome
- Headache
- Nasopharyngitis
- Arthralgia
- Pancreatitis
- Abdominal discomfort
- Asthenia
- Back pain
- Flatulence
- Hypertension
- Nausea
Look up ALOGLIPTIN in the interactive SynDRA portal →